Table 3.
Construct validity: comparison of EQ-5D and SF-6D in terms of patient subgroup differentiation and WOMAC severity level (at baseline) differentiation
| EQ-5D | SF-6D |
Difference |
|
|---|---|---|---|
| (EQ-5D vs. SF-6D) | |||
|
Patient subgroups | |||
| Patients who completed the trial and had no adverse events |
0.695 |
0.694 |
0.001 |
| Patients with at least one AE |
0.583 |
0.640 |
−0.057 |
| Patients with an AE that lead to withdrawal |
0.503 |
0.594 |
−0.091 |
| Patients who discontinued therapy due to lack of efficacy |
0.405 |
0.582 |
−0.176 |
|
WOMAC severity level at baseline | |||
| None to mild |
0.740 |
0.717 |
0.023 |
| Mild to moderate |
0.550 |
0.616 |
−0.066 |
| Moderate to severe |
0.311 |
0.536 |
−0.225 |
| Severe to extreme | 0.180 | 0.461 | −0.281 |